EP2341913A4 - Method of enhancing tgf-beta signalling - Google Patents
Method of enhancing tgf-beta signallingInfo
- Publication number
- EP2341913A4 EP2341913A4 EP09815064A EP09815064A EP2341913A4 EP 2341913 A4 EP2341913 A4 EP 2341913A4 EP 09815064 A EP09815064 A EP 09815064A EP 09815064 A EP09815064 A EP 09815064A EP 2341913 A4 EP2341913 A4 EP 2341913A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- beta signalling
- enhancing tgf
- tgf
- enhancing
- signalling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
- C07C245/04—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9730208P | 2008-09-16 | 2008-09-16 | |
PCT/US2009/056994 WO2010033507A1 (en) | 2008-09-16 | 2009-09-15 | Method of enhancing tgf-beta signalling |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2341913A1 EP2341913A1 (en) | 2011-07-13 |
EP2341913A4 true EP2341913A4 (en) | 2012-02-22 |
EP2341913B1 EP2341913B1 (en) | 2014-11-19 |
Family
ID=42038288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09815064.2A Active EP2341913B1 (en) | 2008-09-16 | 2009-09-15 | Method of enhancing tgf-beta signalling |
Country Status (5)
Country | Link |
---|---|
US (1) | US8487006B2 (en) |
EP (1) | EP2341913B1 (en) |
CN (1) | CN102159219B (en) |
HK (1) | HK1160008A1 (en) |
WO (1) | WO2010033507A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8946201B2 (en) * | 2007-08-27 | 2015-02-03 | Saint Louis University | Methods for inhibiting TGF-β |
WO2010033507A1 (en) | 2008-09-16 | 2010-03-25 | St. Louis University | Method of enhancing tgf-beta signalling |
US10253107B2 (en) | 2012-10-26 | 2019-04-09 | The University Of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
US10322125B2 (en) * | 2013-02-22 | 2019-06-18 | Emory University | TGF-beta enhancing compositions for cartilage repair and methods related thereto |
JPWO2022138700A1 (en) * | 2020-12-23 | 2022-06-30 | ||
WO2023277761A1 (en) * | 2021-06-28 | 2023-01-05 | Gunnar Pejler | New use of monensin |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4058620A (en) * | 1974-07-19 | 1977-11-15 | Hoffmann-La Roche Inc. | Therapeutic agents for improving cardiovascular function |
US4666907A (en) * | 1983-10-05 | 1987-05-19 | Merck Frosst Canada, Inc. | Phenothiazine and derivatives and analogs and use as leukotriene biosynthesis inhibitors |
WO1993025225A1 (en) * | 1992-06-17 | 1993-12-23 | University Of Massachusetts Medical Center | Liposomal formulations for administering to cancer patients |
US5624938A (en) * | 1994-07-18 | 1997-04-29 | The Trustees Of Columbia University In The City Of New York | Use of chloroquine to treat multiple sclerosis |
US20040116407A1 (en) * | 2002-07-11 | 2004-06-17 | Alexis Borisy | Combinations of drugs for the treatment of neoplasms |
WO2006138048A2 (en) * | 2005-06-17 | 2006-12-28 | Immune Control Inc. | Formulations comprising fluphenazine or derivatives thereof |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4456596A (en) | 1981-04-13 | 1984-06-26 | Schaefer Rolf | Wound healing glycoside compositions |
US4423037A (en) | 1982-05-13 | 1983-12-27 | The General Hospital Corporation | Inhibitors of peptide hormone action |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US5654270A (en) | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5118791A (en) | 1989-05-25 | 1992-06-02 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
US5147854A (en) | 1990-05-22 | 1992-09-15 | Hoffmann-La Roche Inc. | Tgf-b compositions and method |
US5824297A (en) | 1990-06-25 | 1998-10-20 | Oncogene Science, Inc. | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof |
US5981606A (en) | 1991-03-01 | 1999-11-09 | Warner-Lambert Company | Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same |
US5444151A (en) | 1992-05-15 | 1995-08-22 | Ludwig Institute For Cancer Research | Platelet derived growth factor antagonists |
JPH08504763A (en) | 1992-10-29 | 1996-05-21 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | Use of TGF-β receptor fragment as a therapeutic agent |
IL107167A (en) | 1993-10-03 | 2000-01-31 | Raziel Lurie | Compositions containing relaxin for treatment of alopecia and related conditions |
US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
US5981621A (en) * | 1996-02-29 | 1999-11-09 | Closure Medical Corporation | Monomeric compositions effective as wound closure devices |
US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
GB9518509D0 (en) | 1995-09-11 | 1995-11-08 | Rowghani Karim | Novel use of a known compound |
JPH1067674A (en) | 1996-06-19 | 1998-03-10 | Advanced Sukin Res Kenkyusho:Kk | Abnormal accumulation suppressor of extracellular matrix |
AU6620596A (en) * | 1996-07-25 | 1998-02-20 | Victoria University Of Manchester, The | Use of transglutaminase modulators to promote wound healing |
US6337320B1 (en) | 1996-10-11 | 2002-01-08 | Thione International, Inc. | Reparatives for ultraviolet radiation skin damage |
US6500920B1 (en) | 1997-06-19 | 2002-12-31 | St. Louis University | Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor |
US7723473B2 (en) | 1997-06-19 | 2010-05-25 | St. Louis University | Peptide antagonists of TGF-beta family members and therapeutic uses thereof |
BRPI9807124B8 (en) | 1997-12-05 | 2021-05-25 | Cosmoferm Bv | compositions comprising a combination of a free sphingoid base and a ceramide and uses thereof. |
US6806358B1 (en) | 1997-12-16 | 2004-10-19 | University Of California San Diego | Peptide inhibitor of TGF-β growth factors |
WO1999034823A2 (en) | 1998-01-09 | 1999-07-15 | University Of Utah | METHODS FOR PREVENTING AND TREATING FIBROTIC DISEASES RESULTING FROM ACCUMULATION OF EXCESS EXTRACELLULAR MATRIX INDUCED BY TGFβ USING RENIN INHIBITORS |
ES2146552B1 (en) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | INHIBITING PEPTIDES OF TGF / 31 |
WO2000040227A2 (en) | 1999-01-05 | 2000-07-13 | University Of Utah | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
US20040022758A1 (en) | 2000-09-11 | 2004-02-05 | Toshihiko Hibino | Hair tonics and method of screening the same |
US6649588B1 (en) | 2000-10-05 | 2003-11-18 | North Shore - Long Island Jewish Research Institute | Inhibition of TGF-β and uses thereof |
OA13136A (en) | 2001-05-21 | 2006-12-13 | Nektar Therapeutics | Pulmonary administration of chemically modified insulin. |
EP1534737A4 (en) | 2002-04-29 | 2007-10-31 | Univ Saint Louis | Peptide antagonists of tgf-beta family members and therapeutic uses thereof |
US20040229791A1 (en) | 2002-12-31 | 2004-11-18 | Jung San Huang | Compositions and methods of modulating TGF-beta activity by fatty acids |
US20050250801A1 (en) * | 2003-03-10 | 2005-11-10 | Kunwar Shailubhai | Method of treating cancer with azaspirane compositions |
AU2003901205A0 (en) * | 2003-03-14 | 2003-04-03 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic and prophylactic compositions and uses therefor |
US7741283B2 (en) | 2003-10-17 | 2010-06-22 | St. Louis University | Compositions and methods for inhibiting cell proliferation |
GB2426517A (en) * | 2003-11-21 | 2006-11-29 | Univ Newcastle Res Ass | Methods and agents for inhibiting dynamin-dependent endocytosis |
US8535709B2 (en) | 2004-12-13 | 2013-09-17 | Southeastern Medical Technologies, Llc | Agents for controlling biological fluids and methods of use thereof |
CA2606598C (en) * | 2005-05-13 | 2014-12-23 | Topotarget Uk Limited | Pharmaceutical formulations of hdac inhibitors |
US8440695B2 (en) * | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
US7973022B2 (en) * | 2006-02-17 | 2011-07-05 | Idexx Laboratories, Inc. | Fluoroquinolone carboxylic acid salt compositions |
US8110655B2 (en) | 2006-11-13 | 2012-02-07 | Auxagen, Inc. | Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor |
US8946201B2 (en) | 2007-08-27 | 2015-02-03 | Saint Louis University | Methods for inhibiting TGF-β |
WO2009114700A2 (en) * | 2008-03-12 | 2009-09-17 | The Trustees Of Columbia University In The City Of New York | Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion |
WO2010033507A1 (en) | 2008-09-16 | 2010-03-25 | St. Louis University | Method of enhancing tgf-beta signalling |
-
2009
- 2009-09-15 WO PCT/US2009/056994 patent/WO2010033507A1/en active Application Filing
- 2009-09-15 EP EP09815064.2A patent/EP2341913B1/en active Active
- 2009-09-15 CN CN200980136369.2A patent/CN102159219B/en active Active
- 2009-09-15 US US12/560,136 patent/US8487006B2/en active Active
-
2012
- 2012-01-17 HK HK12100521.4A patent/HK1160008A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4058620A (en) * | 1974-07-19 | 1977-11-15 | Hoffmann-La Roche Inc. | Therapeutic agents for improving cardiovascular function |
US4666907A (en) * | 1983-10-05 | 1987-05-19 | Merck Frosst Canada, Inc. | Phenothiazine and derivatives and analogs and use as leukotriene biosynthesis inhibitors |
WO1993025225A1 (en) * | 1992-06-17 | 1993-12-23 | University Of Massachusetts Medical Center | Liposomal formulations for administering to cancer patients |
US5624938A (en) * | 1994-07-18 | 1997-04-29 | The Trustees Of Columbia University In The City Of New York | Use of chloroquine to treat multiple sclerosis |
US20040116407A1 (en) * | 2002-07-11 | 2004-06-17 | Alexis Borisy | Combinations of drugs for the treatment of neoplasms |
WO2006138048A2 (en) * | 2005-06-17 | 2006-12-28 | Immune Control Inc. | Formulations comprising fluphenazine or derivatives thereof |
Non-Patent Citations (4)
Title |
---|
C.-L. CHEN ET AL: "Inhibitors of clathrin-dependent endocytosis enhance TGF signaling and responses", JOURNAL OF CELL SCIENCE, vol. 122, no. 11, 20 May 2009 (2009-05-20), pages 1863 - 1871, XP055015299, ISSN: 0021-9533, DOI: 10.1242/jcs.038729 * |
GIANNI M. DI GUGLIELMO ET AL: "Distinct endocytic pathways regulate TGF-[beta] receptor signalling and turnover", NATURE CELL BIOLOGY, vol. 5, no. 5, 28 April 2003 (2003-04-28), pages 410 - 421, XP055015383, ISSN: 1465-7392, DOI: 10.1038/ncb975 * |
See also references of WO2010033507A1 * |
SEYED ALI MOUSAVI ET AL: "Clathrin-dependent endocytosis", BIOCHEMICAL JOURNAL, vol. 377, no. 1, 1 January 2004 (2004-01-01), pages 1 - 16, XP055014586, ISSN: 0264-6021, DOI: 10.1042/BJ20031000 * |
Also Published As
Publication number | Publication date |
---|---|
EP2341913B1 (en) | 2014-11-19 |
CN102159219B (en) | 2015-06-24 |
US20100075923A1 (en) | 2010-03-25 |
EP2341913A1 (en) | 2011-07-13 |
WO2010033507A1 (en) | 2010-03-25 |
HK1160008A1 (en) | 2012-08-10 |
CN102159219A (en) | 2011-08-17 |
US8487006B2 (en) | 2013-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0820927D0 (en) | Method | |
GB0803107D0 (en) | Method | |
GB0818093D0 (en) | Method | |
GB0822836D0 (en) | Method | |
GB0810418D0 (en) | Method | |
GB0806569D0 (en) | Methods | |
GB0815428D0 (en) | Method | |
GB0813599D0 (en) | Method | |
GB0807409D0 (en) | Method | |
GB0807410D0 (en) | Method | |
GB0804981D0 (en) | Method | |
GB0804690D0 (en) | Method | |
HK1147481A1 (en) | Polymorphic form | |
EP2309852A4 (en) | Novel method | |
GB0809404D0 (en) | Method | |
EP2341913A4 (en) | Method of enhancing tgf-beta signalling | |
ZA201101329B (en) | Recarburisation method | |
ZA201008728B (en) | Method | |
GB0805862D0 (en) | Method | |
GB0813494D0 (en) | Method | |
GB0922037D0 (en) | Method | |
GB0812102D0 (en) | Method | |
GB2488685B (en) | Method of adapting pavement | |
GB0806186D0 (en) | Method | |
GB0811166D0 (en) | Method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110413 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20120119 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20120113BHEP Ipc: A61P 29/00 20060101AFI20120113BHEP Ipc: A61K 31/166 20060101ALI20120113BHEP Ipc: A61K 31/5415 20060101ALI20120113BHEP Ipc: A61K 31/724 20060101ALI20120113BHEP Ipc: A61P 9/00 20060101ALI20120113BHEP Ipc: A61K 31/35 20060101ALI20120113BHEP Ipc: A61K 31/366 20060101ALI20120113BHEP Ipc: A61K 31/40 20060101ALI20120113BHEP Ipc: A61P 9/10 20060101ALI20120113BHEP Ipc: A61K 31/18 20060101ALI20120113BHEP Ipc: A61K 31/505 20060101ALI20120113BHEP Ipc: A61K 31/404 20060101ALI20120113BHEP Ipc: A61K 31/47 20060101ALI20120113BHEP Ipc: A61P 17/00 20060101ALI20120113BHEP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602009027899 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031708800 Ipc: A61P0029000000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/404 20060101ALI20140410BHEP Ipc: A61P 35/00 20060101ALI20140410BHEP Ipc: A61K 31/18 20060101ALI20140410BHEP Ipc: A61K 31/166 20060101ALI20140410BHEP Ipc: A61P 17/00 20060101ALI20140410BHEP Ipc: A61K 31/5415 20060101ALI20140410BHEP Ipc: A61P 29/00 20060101AFI20140410BHEP Ipc: A61K 31/366 20060101ALI20140410BHEP Ipc: A61K 31/505 20060101ALI20140410BHEP Ipc: A61K 31/40 20060101ALI20140410BHEP Ipc: A61P 9/10 20060101ALI20140410BHEP Ipc: A61P 9/00 20060101ALI20140410BHEP Ipc: A61K 31/724 20060101ALI20140410BHEP Ipc: A61K 31/47 20060101ALI20140410BHEP Ipc: A61K 31/35 20060101ALI20140410BHEP Ipc: C07C 245/04 20060101ALI20140410BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20140610 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 696644 Country of ref document: AT Kind code of ref document: T Effective date: 20141215 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009027899 Country of ref document: DE Effective date: 20141231 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20141119 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 696644 Country of ref document: AT Kind code of ref document: T Effective date: 20141119 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150219 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150319 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150319 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150220 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009027899 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20150820 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150915 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150915 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150930 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150930 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20090915 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141119 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602009027899 Country of ref document: DE Representative=s name: MAIWALD GMBH, DE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230808 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230914 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240926 Year of fee payment: 16 |